Appeals Court hears CRISPR-Cas9 patent case

The United States Court of Appeals for the Federal Circuit heard oral arguments Monday in patent litigation over CRISPR-Cas9 gene editing technology. A group representing the University of California argued that the U.S. Patent Trial and Appeal Board (PTAB) failed to

Read the full 416 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE